中德临床肿瘤学杂志（英文版）2009，Vol.8Issue(2)：65-68,4.DOI:10.1007/s10330-008-0142-8
康莱特胶丸联合TACE治疗中晚期原发性肝癌的疗效观察
Effects of kanglaite capsules combined with transcatheter arterial chemoembolization(TACE) on patients with mid or late-stage primary hepatocellular carcinoma(HCC)
Daojun Li 1Xinhua Xu 2Dan Bao 3Feng Xue 2Delan Dai3
作者信息
- 1. The First College of Clinical Medical Science,Three Gorges University,Yichang 443003,China
- 2. Department of Oncology,Yichang Central People's Hospital,Yichang 443003,China
- 3. Oncology Institute,Three Gorges University,Yichang 443003,China
- 折叠
摘要
Abstract
Objective:To observe the clinical effects of kanglaite (KLT)capsules combined with transcatheter arterial chemo- embolization(TACE)in treating patients with mid or late-stage primary hepatocellular carcinoma (HCC).Methods:Sixty-five cases were randomly divided into 2 groups.32 patients in combination group received the treatment of KLT capsules+TACE and 33 patients in control group were treared with TACE alone.The objective response rate(RR).serum alpha fetoprotein (AFP),peripheral blood T lymphocyte subgroups(T-LS),quality of life(QOL),time to progression(TTP)and adverse reaction were observed and compared between 2 groups.Results:The objective response rate and serum alpha fetoprotein levels had no significant difference between the two groups (P＞0.05).Combination group was superior to control group in quality of life(QOL).time to progression(TTP),peripheral blood T lymphocyte subgroups(CD3+,CD4+,CD4+＼CD8 ratio)and liver adverse reactions,with significant differences (P＜0.05).Conclusion:KLT capsules combined with TACE is an effective method to treat primary hepatocellular carcinoma (HCC) patients who have lost the opportunity of surgical therapy.关键词
kanglaite (KLT) capsules/primaw hepatocellular carcinoma(HCC)/chemotherapy/embolizationKey words
kanglaite (KLT) capsules/primaw hepatocellular carcinoma(HCC)/chemotherapy/embolization分类
医药卫生引用本文复制引用
Daojun Li,Xinhua Xu,Dan Bao,Feng Xue,Delan Dai..康莱特胶丸联合TACE治疗中晚期原发性肝癌的疗效观察[J].中德临床肿瘤学杂志（英文版）,2009,8(2):65-68,4.
